-The Indian Express Prime Minister Narendra Modi's US visit is likely to throw up highly contentious Intellectual Property Rights issues. Indeed, for the last several years, US drug majors and their European counterparts have lobbied hard to demonise the Indian patent regime. But the government must continue to defend the law and stand its ground. Particularly since our own industrial moguls have caved in and are less vocal about their opposition...
More »SEARCH RESULT
IPR policy in the works
-The Telegraph New Delhi: The government plans to come out with a policy on Intellectual Property Rights (IPR) within a few months, with developed nations such as the US and the EU raising concerns over the country's patent rules. "India does not have an IPR policy. This is the first time we are coming out with a policy. IPR policy issues have been hanging fire for quite a long time," commerce and...
More »Defending India’s patent law-Prabha Sridevan
-The Hindu No one can attack India's well-founded Intellectual Property regime as being weak merely because a drug that is claimed to be an invention fails the test of law India and its intellectual property (IP) laws have been the subject of sharp criticism recently. Now, there is talk of the government invoking emergency provisions with regard to Dasatinib, a cancer drug. The decibel level may go up several notches. Let us look...
More »Onus on the state-Sagnik Dutta
-Frontline A Delhi High Court verdict says the State government is bound to ensure that poor and vulnerable sections of society have access to treatment for rare and chronic diseases. SEVEN-YEAR-OLD Mohammed Ahmed Khan looked on helplessly as his father, Sirajuddin, narrated the sordid tale of the loss of four of his children to Gaucher's disease, a rare genetic disease that requires lifelong, exorbitantly expensive enzyme replacement therapy. Sirajuddin, a rickshaw...
More »Friction over drug patents
-The Hindu Differences over Intellectual Property Rights (IPRs) have emerged as a strong undercurrent in India's economic relations with the U.S. The attempt by the influential pharmaceutical lobby to stymie India's efforts to ensure the supply of medicines at affordable rates without violating existing treaty commitments, requires a principled response from New Delhi. At the core of the issue is what Columbia University Professor Arvind Panagariya calls "the hijacking of...
More »